Androgen receptor expression in low grade serous ovarian cancer; clinical considerations in the diagnosis, treatment and surveillance of disease in a transgender male

Stacy A Smrz; Graham Chapman; Jennifer Gordon; Christina Bagby; Alessandra Nascimento; Lindsay Ferguson

doi:10.1016/j.gore.2023.101190

Androgen receptor expression in low grade serous ovarian cancer; clinical considerations in the diagnosis, treatment and surveillance of disease in a transgender male

Gynecol Oncol Rep. 2023 Apr 15:47:101190. doi: 10.1016/j.gore.2023.101190. eCollection 2023 Jun.

Authors

Stacy A Smrz¹, Graham Chapman¹, Jennifer Gordon¹, Christina Bagby², Alessandra Nascimento², Lindsay Ferguson¹

Affiliations

¹ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States.
² Department of Pathology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States.

Abstract

•Low grade serous (LGS) ovarian cancer is an uncommon cancer.•Androgen receptor expression testing is not routinely performed in patients with LGS ovarian cancer.•Systemic androgen levels may be elevated in patients with PCOS or those taking exogenous testosterone.•Consideration should be made to include androgen receptor testing for these patients.

Keywords: Androgen receptor; Ovarian cancer; Transgender male.

Publication types

Case Reports